CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Screening for Atrial Fibrillation With ECG: USPSTF Recommendation Major infections after bypass surgery and stenting: an overlooked but fatal complication A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Defining Staged Procedures for Percutaneous Coronary Intervention Trials A Guidance Document Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study

Review Article2017 Feb 7;69(5):556-569.

JOURNAL:J Am Coll Cardiol. Article Link

Mode of Death in Heart Failure With Preserved Ejection Fraction

Vaduganathan M, Patel RB, Butler J et al. Keywords: epidemiology; mortality; outcomes

ABSTRACT


Little is known about specific modes of death in patients with heart failure with preserved ejection fraction(HFpEF). Herein, the authors critically appraise the current state of data and offer potential future directions. They conducted a systematic review of 1,608 published HFpEF papers from January 1, 1985, to December 31, 2015, which yielded 8 randomized clinical trials and 24 epidemiological studies with mode-of-death data. Noncardiovascular modes of death represent an important competing risk in HFpEF. Although sudden death accounted for ∼25% to 30% of deaths in trials, its definition is nonspecific; it is unclear what proportion represents arrhythmic deaths. Moving forward, reporting and definitions of modes of death must be standardized and tailored to the HFpEF population. Broad-scale systematic autopsies and long-term rhythm monitoring may clarify the underlying pathology and mechanisms driving mortal events. There is an unmet need for a longitudinal multicenter, global registry of patients with HFpEF to map its natural history.